Status:
NOT_YET_RECRUITING
Real-World Study on the Safety and Effectiveness of IL-23 Inhibitors for Inflammatory Bowel Disease in China
Lead Sponsor:
Sixth Affiliated Hospital, Sun Yat-sen University
Conditions:
Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis)
Eligibility:
All Genders
18+ years
Brief Summary
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), has shown greatly improved outcomes with biologic therapies. However, nearly half of patients still experi...
Eligibility Criteria
Inclusion
- Adults aged 18 years or older, any gender. Formally diagnosed with ulcerative colitis (UC) or Crohn's disease (CD). Determined by the treating physician to require initiation of IL-23 inhibitor (IL-23i) therapy for the first time.
Exclusion
- Currently enrolled in or planning to participate in any other interventional clinical study.
- Contraindications to IL-23i treatment as specified in the drug label. Considered by the investigator to be unsuitable for participation in the study for any reason.
Key Trial Info
Start Date :
October 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2028
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT07184138
Start Date
October 1 2025
End Date
November 1 2028
Last Update
September 19 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.